No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PFE240719P40000
- 9.55
- -0.65-6.37%
15min DelayTrading Jul 18 10:01 ET
9.55High9.55Low
9.55Open10.20Pre Close1 Volume3 Open Interest40.00Strike Price955.00Turnover0.00%IV-0.26%PremiumJul 19, 2024Expiry Date9.63Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.15Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Express News | President Biden's Doctor Says President Biden's Vital Signs Remain Normal; He Will Continue To Conduct U.S. Business; Continues To Receive Paxlovid; Still Experiencing Mild Covid-19 Symptoms
Pfizer Stock Nears Golden Cross, Signals Potential Upside With Strong Oncology Portfolio
Pfizer Inc (NYSE:PFE), one of the world's largest pharmaceutical firms, is on the verge of a bullish Golden Cross, a significant technical indicator suggesting potential upward momentum for the stock.
Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion
New York, NY and Saint-Herblain (France), July 17, 2024 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the participants of the Phase 3 trial “Vaccine Against Lyme for Outdoor Recreationists” (VALOR) have completed the primary vaccination series (three doses) of Lyme disease vaccine candidate VLA15. Participants will be monitored for the occurrence of Lyme disease cases until the end of the Lyme disease season in 2025.
Pfizer Options Spot-On: On July 17th, 236.13K Contracts Were Traded, With 2.92 Million Open Interest
On July 17th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 236.13K options for the day, of which put options accounted for 21.65% of the total transactions, and
Express News | OPKO Health Inc: Also Permits OPKO to Maintain Full Benefit of $100 Mln of Remaining Potential Milestone Payments From Pfizer
Express News | OPKO Health Enters Into $250M Non-Dilutive Note Purchase Agreement With HealthCare Royalty Secured By Profit Share Payments From Pfizer For NGENLA
Comments
$Pfizer(PFE.US$ this is the only healthcare share rise today . what’s happening to others
“History Doesn’t Repeat Itself, but It Often Rhymes” – Mark Twain
“Be Fearful When Others Are Greedy and Greedy When Others Are Fearful” – Warren Buffett
“Success means being very patient, but aggressive when it’s time.” – Charlie Munger
My previous posts,
I am looking forward to upcoming Fed cuts
Will Nvidia Pullback to 90 ?
$NVIDIA(NVDA.US$ $iShares Russell 2000 ETF(IWM.US$ $MarketAxess(MKTX.US$ $Pfizer(PFE.US$ $Vanguard Real Estate ETF(VNQ.US$ $Global Payments(GPN.US$
“Be Fearful When Others Are Greedy and Greedy When Others Are Fearful” – Warren Buffett
“Success means being very patient, but aggressive when it’s time.” – Charlie Munger
My previous posts,
I am looking forward to upcoming Fed cuts
Will Nvidia Pullback to 90 ?
$NVIDIA(NVDA.US$ $iShares Russell 2000 ETF(IWM.US$ $MarketAxess(MKTX.US$ $Pfizer(PFE.US$ $Vanguard Real Estate ETF(VNQ.US$ $Global Payments(GPN.US$
loading...
3
Why do you think $Pfizer(PFE.US$ decided to progress with Danuglipron? (![]()
Can't give up this huge market?
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
+1
5
Read more